The Experts below are selected from a list of 1896 Experts worldwide ranked by ideXlab platform
Michael M Mcneil - One of the best experts on this subject based on the ideXlab platform.
-
Myopericarditis after vaccination vaccine adverse event reporting system vaers 1990 2018
Vaccine, 2021Co-Authors: Michael M Mcneil, Kerry Welsh, Paige L Marquez, Ming Yan, Maria CanoAbstract:BACKGROUND Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of Myopericarditis after vaccines licensed for use in the United States. METHODS We identified U.S. reports of Myopericarditis received by VAERS during 1990-2018 that met a published case definition for Myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of Myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of Myopericarditis after vaccination. RESULTS VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as Myopericarditis. Most (79%) Myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of Myopericarditis. Data mining revealed disproportionate reporting of Myopericarditis only after smallpox vaccine. CONCLUSIONS Despite the introduction of new vaccines over the years, Myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, Myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines.
-
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
Vaccine, 2021Co-Authors: Michael M Mcneil, Paige L Marquez, Ming Yan, Kerry J Welsh, Maria V CanoAbstract:Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of Myopericarditis after vaccines licensed for use in the United States. We identified U.S. reports of Myopericarditis received by VAERS during 1990-2018 that met a published case definition for Myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of Myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of Myopericarditis after vaccination. VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as Myopericarditis. Most (79%) Myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of Myopericarditis. Data mining revealed disproportionate reporting of Myopericarditis only after smallpox vaccine. Despite the introduction of new vaccines over the years, Myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, Myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines. Published by Elsevier Ltd.
Maria Cano - One of the best experts on this subject based on the ideXlab platform.
-
Myopericarditis after vaccination vaccine adverse event reporting system vaers 1990 2018
Vaccine, 2021Co-Authors: Michael M Mcneil, Kerry Welsh, Paige L Marquez, Ming Yan, Maria CanoAbstract:BACKGROUND Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of Myopericarditis after vaccines licensed for use in the United States. METHODS We identified U.S. reports of Myopericarditis received by VAERS during 1990-2018 that met a published case definition for Myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of Myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of Myopericarditis after vaccination. RESULTS VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as Myopericarditis. Most (79%) Myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of Myopericarditis. Data mining revealed disproportionate reporting of Myopericarditis only after smallpox vaccine. CONCLUSIONS Despite the introduction of new vaccines over the years, Myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, Myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines.
Maria V Cano - One of the best experts on this subject based on the ideXlab platform.
-
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
Vaccine, 2021Co-Authors: Michael M Mcneil, Paige L Marquez, Ming Yan, Kerry J Welsh, Maria V CanoAbstract:Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of Myopericarditis after vaccines licensed for use in the United States. We identified U.S. reports of Myopericarditis received by VAERS during 1990-2018 that met a published case definition for Myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of Myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of Myopericarditis after vaccination. VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as Myopericarditis. Most (79%) Myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of Myopericarditis. Data mining revealed disproportionate reporting of Myopericarditis only after smallpox vaccine. Despite the introduction of new vaccines over the years, Myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, Myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines. Published by Elsevier Ltd.
John D. Grabenstein - One of the best experts on this subject based on the ideXlab platform.
-
Myopericarditis following smallpox vaccination.
American journal of epidemiology, 2004Co-Authors: Mark K. Arness, James R Riddle, Robert E Eckart, Suzanne S. Love, Timothy S. Wells, Renata J. M. Engler, Limone C. Collins, Sharon L. Ludwig, J. Edwin Atwood, John D. GrabensteinAbstract:Myopericarditis has been a rare or unrecognized event after smallpox vaccinations with the New York City Board of Health strain of vaccinia virus (Dryvax; Wyeth Laboratories, Marietta, Pennsylvania). In this article, the authors report an attributable incidence of at least 140 clinical cases of Myopericarditis per million primary smallpox vaccinations with this strain of vaccinia virus. Fifty-eight males and one female aged 21-43 years with confirmed or probable acute Myopericarditis were detected following vaccination of 492,730 US Armed Forces personnel from December 15, 2002, through September 30, 2003. The cases were identified through sentinel reporting to military headquarters, active surveillance using the Defense Medical Surveillance System, or reports to the Vaccine Adverse Event Reporting System. The observed incidence (16.11/100,000) of Myopericarditis over a 30-day observation window among 347,516 primary vaccinees was nearly 7.5-fold higher than the expected rate of 2.16/100,000 (95% confidence interval: 1.90, 2.34) among nonvaccinated, active-duty military personnel, while the incidence of 2.07/100,000 among 145,155 revaccinees was not statistically different from the expected background rate. The cases were predominantly male (58/59; 98.3%) and White (51/59; 86.4%), both statistically significant associations (p = 0.0147 and p = 0.05, respectively).
-
Smallpox vaccination and Myopericarditis: a clinical review.
Journal of the American College of Cardiology, 2004Co-Authors: Dimitri C. Cassimatis, J. Edwin Atwood, Renata M Engler, Peter E. Linz, John D. Grabenstein, Marina N. VernalisAbstract:Smallpox is a devastating viral illness that was eradicated after an aggressive, widespread vaccination campaign. Routine U.S. childhood vaccinations ended in 1972, and routine military vaccinations ended in 1990. Recently, the threat of bioterrorist use of smallpox has revived the need for vaccination. Over 450,000 U.S. military personnel received the vaccination between December 2002 and June 2003, with rates of non-cardiac complications at or below historical levels. The rate of cardiac complications, however, has been higher than expected, with two confirmed cases and over 50 probable cases of Myopericarditis after vaccination reported to the Department of Defense Smallpox Vaccination Program. The practicing physician should use the history and physical, electrocardiogram, and cardiac biomarkers in the initial evaluation of a post-vaccination patient with chest pain. Echocardiogram, cardiac catheterization, magnetic resonance imaging, nuclear imaging, and cardiac biopsy may be of use in further workup. Treatment is with non-steroidal anti-inflammatory agents, four to six weeks of limited exertion, and conventional heart failure treatment as necessary. Immune suppressant therapy with steroids may be uniquely beneficial in Myopericarditis related to smallpox vaccination, compared with other types of Myopericarditis. If a widespread vaccination program is undertaken in the future, many more cases of post-vaccinial Myopericarditis could be seen. Practicing physicians should be aware that smallpox vaccine-associated Myopericarditis is a real entity, and symptoms after vaccination should be appropriately evaluated, treated if necessary, and reported to the Vaccine Adverse Events Reporting System.
Paige L Marquez - One of the best experts on this subject based on the ideXlab platform.
-
Myopericarditis after vaccination vaccine adverse event reporting system vaers 1990 2018
Vaccine, 2021Co-Authors: Michael M Mcneil, Kerry Welsh, Paige L Marquez, Ming Yan, Maria CanoAbstract:BACKGROUND Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of Myopericarditis after vaccines licensed for use in the United States. METHODS We identified U.S. reports of Myopericarditis received by VAERS during 1990-2018 that met a published case definition for Myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of Myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of Myopericarditis after vaccination. RESULTS VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as Myopericarditis. Most (79%) Myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of Myopericarditis. Data mining revealed disproportionate reporting of Myopericarditis only after smallpox vaccine. CONCLUSIONS Despite the introduction of new vaccines over the years, Myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, Myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines.
-
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
Vaccine, 2021Co-Authors: Michael M Mcneil, Paige L Marquez, Ming Yan, Kerry J Welsh, Maria V CanoAbstract:Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of Myopericarditis after vaccines licensed for use in the United States. We identified U.S. reports of Myopericarditis received by VAERS during 1990-2018 that met a published case definition for Myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of Myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of Myopericarditis after vaccination. VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as Myopericarditis. Most (79%) Myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of Myopericarditis. Data mining revealed disproportionate reporting of Myopericarditis only after smallpox vaccine. Despite the introduction of new vaccines over the years, Myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, Myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines. Published by Elsevier Ltd.
